Each Baqsimi device includes 1 dose of glucagon and cannot be refused. The Food and Drug Administration (FDA) has expanded the approval of Baqsimi (glucagon) nasal powder to include the treatment of ...

Amphastar Pharmaceuticals shows promising growth potential with its diverse product offerings, including the nasally administered glucagon treatment BAQSIMI and the over-the-counter inhalant Primatene ...